Some approaches can upregulate the target antigen expression to enhance CAR-T efficacy, as reported for upregulation of BCMA by a γ-secretase inhibitor in myeloma [20], and GD2 upregulation upon EZH2 inhibition in Ewing Sarcoma [21]. Here, TNFRSF17 is linked to plasma cell myeloma.